Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with chronic kidney disease (CKD) stage 3 (creatinine clearance \[CrCl\]/ glomerular filtration rate \[GFR\] 30 to 59 milliliter per minutes per 1.73 meter square \[mL/min/1.73m\^2\]) or Stage 4 (CrCl/GFR 15-29 mL/min/1.73m\^2) who did not require dialysis. CrCl/GFR was estimated with the Cockcroft-Gault equation or the abbreviated Modification of Diet in Renal Disease (MDRD) equation~* Anemia defined as baseline Hb concentration less than (\<) 10.5 gram per deciliter (g/dL)~Exclusion Criteria:~* Previous therapy with any ESA within 12 weeks prior to screening~* Renal allograft in place~* Immunosuppressive therapy in the 12 weeks prior to screening~* Overt gastrointestinal bleeding and red blood cells (RBC) transfusions within 8 weeks before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mircera (Type: EXPERIMENTAL): Participants will receive Mircera (Methoxy polyethylene glycol-epoetin beta), administered subcutaneously (SC) at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.
- Darbepoetin Alfa (Type: ACTIVE_COMPARATOR): Participants will receive darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).